Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?

导出 LinkOut

翻译打印收藏纠错

作者： Anousheh,Shafa ^[1] ; A Brooke,Watkins ^[1] ; Michaela E,McGree ^[2] ; S John,Weroha ^[3] ; Andrea E,Wahner Hendrickson ^[3] ; Matthew S,Block ^[3] ; Carrie L,Langstraat ^[4] ; Robert D,McBane ^[5] ; Jamie N,Bakkum-Gamez ^[1] ; Amanika,Kumar ^[6]

作者单位： Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America. ^[1] Mayo Clinic, Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Rochester, MN, United States of America. ^[2] Mayo Clinic, Department of Oncology, Rochester, MN, United States of America. ^[3] Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America; Mayo Clinic, Department of Oncology, Rochester, MN, United States of America. ^[4] Mayo Clinic, Department of Cardiovascular Disease, Rochester, MN, United States of America. ^[5] Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America. Electronic address: kumar.amanika@mayo.edu. ^[6]

关键词 Direct-acting oral anticoagulation Neoadjuvant chemotherapy Ovarian cancer Thromboprophylaxis Venous thromboembolism